These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20681357)

  • 21. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause?
    Griffin ME; Feder A; Tamborlane WV
    Diabetes Care; 2001 Jan; 24(1):174. PubMed ID: 11194227
    [No Abstract]   [Full Text] [Related]  

  • 22. Lispro insulin-induced lipoatrophy: a new case.
    Al-Khenaizan S; Al Thubaiti M; Al Alwan I
    Pediatr Diabetes; 2007 Dec; 8(6):393-6. PubMed ID: 18036067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoatrophy in children with type 1 diabetes: an increasing incidence?
    Kordonouri O; Biester T; Schnell K; Hartmann R; Tsioli C; Fath M; Datz N; Danne T
    J Diabetes Sci Technol; 2015 Mar; 9(2):206-8. PubMed ID: 25411060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature.
    Holstein A; Stege H; Kovacs P
    Expert Opin Drug Saf; 2010 Mar; 9(2):225-31. PubMed ID: 20001763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.
    Radermecker RP; Piérard GE; Scheen AJ
    Am J Clin Dermatol; 2007; 8(1):21-8. PubMed ID: 17298103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes.
    Eugster EA; Francis G;
    Pediatrics; 2006 Oct; 118(4):e1244-9. PubMed ID: 17015512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Injection site lipoatrophy: a rare complication of recombinant human insulin.
    Chakraborty PP; Bhattacharjee R
    J Assoc Physicians India; 2010 Oct; 58():630. PubMed ID: 21510114
    [No Abstract]   [Full Text] [Related]  

  • 28. Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes.
    Weintrob N; Shalitin S; Phillip M
    Isr Med Assoc J; 2004 May; 6(5):271-5. PubMed ID: 15151365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lipoatrophic diabetes].
    Kusakabe T; Ebihara K; Nakao K
    Nihon Rinsho; 2006 Sep; Suppl 3():110-3. PubMed ID: 17022511
    [No Abstract]   [Full Text] [Related]  

  • 30. Images in clinical medicine. Injection-site lipoatrophy.
    Sackey AH
    N Engl J Med; 2009 Nov; 361(19):e41. PubMed ID: 19890122
    [No Abstract]   [Full Text] [Related]  

  • 31. Rediscovery of insulin pump treatment of childhood type 1 diabetes.
    Weinzimer SA; Doyle EA; Steffen AT; Sikes KA; Tamborlane WV
    Minerva Med; 2004 Apr; 95(2):85-92. PubMed ID: 15272243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus.
    Danne T
    Clin Ther; 2007; 29 Suppl D():S145-52. PubMed ID: 18191066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Guidelines concerning insulin dosage in children and adolescents with type 1 diabetes on continuous subcutaneous insulin infusion].
    Szypowska A; Pańkowska E; Lipka M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):45-50. PubMed ID: 16704861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial.
    Stainer R; Matthews S; Arshad SH; McDonald S; Robinson J; Schapira C; Foote KD; Baird-Snell M; Gregory T; Pollock I; Stevens MT; Edwards AM
    Br J Dermatol; 2005 Feb; 152(2):334-41. PubMed ID: 15727648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment with insulin pump during hospital care should be questioned. Three cases illustrate the risk of ketoacidosis].
    Gubrianska D; Moberg E; Palmér M
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1967-8. PubMed ID: 19764373
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication.
    Ampudia-Blasco FJ; Girbes J; Carmena R
    Diabetes Care; 2005 Dec; 28(12):2983. PubMed ID: 16306570
    [No Abstract]   [Full Text] [Related]  

  • 39. [Local lipohypertrophy in insulin treatment].
    Herold DA; Albrecht G
    Hautarzt; 1993 Jan; 44(1):40-2. PubMed ID: 8436508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New methods in insulin treatment].
    Neuwirth G
    Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.